This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Pharma Sector
The global pharma sector in Q1 2024 witnessed deals worth $65 billion, a growth of 1% compared to Q1 2023. In terms of deal volume also, there was a growth of 70% to record 312 M&A deals in Q1 2024. The Pharma sector recorded 15 mega deals (defined as any deal valued at more than $1 billion) in 2023, an increase of 88% compared to Q1 2023.Scope
- This report provides an overview of merger and acquisition activity globally in Q1 2024 in Pharma Sector
- It identifies the themes driving most notable to deals announced in Q1 2024 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Table of Contents
- Executive Summary
- Review of Pharma M&A Market - Q1 2024
- Top Pharma M&A Deals by Sector - Q1 2024
- Pharma M&A Deals Analysis by Geography - Q1 2024
- Top Themes Driving Pharma M&A Activity - Q1 2024
- Appendix 1: Deal Selection Criteria
- Appendix 2: Top Themes for 2024 in Pharma
- Appendix 3: Thematic Research Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk
- Lonza Group
- Roquette
- AstraZeneca
- Bondalti
- China Resources Double-Crane Pharmaceutical
- Gilead Sciences
- Jazz Pharmaceuticals
- Qingdao Ocean Innovative Products Investment
- Qingdao Ocean New Kinetic Energy Products Investment Fund
- Novo Holdings
- Novartis
- Exponent Private Equity
- Sanofi
- Vision Sensing Acquisition
- GSK
- Floki Holding
- Johnson & Johnson
- Merck
- Novartis
- Cardior Pharmaceuticals
- F. Hoffmann-La Roche
- International Flavors & Fragrances
- Fusion Pharmaceuticals
- Amolyt Pharma
- Ercros
- China Resources Zizhu Pharmaceutical
- CymaBay Therapeutics
- Redx Pharma
- Cp Pharmaceutical Qingdao
- Catalent
- MorphoSys
- Chanelle Pharma
- Inhibrx
- Mediforum
- Aiolos Bio
- Alvogen Malta
- Ambrx Biopharma
- Harpoon Therapeutics
- Calypso Biotech
